 Proactive Investors USA & Canada |
AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials
Genetic Engineering News Dynavax Technologies will receive a $3 million payment from AstraZeneca to fund the initiation of clinical trials with their partnered asthma drug AZD 1419. The payment comes as part of the firms' amended collaboration to accelerate the start of … AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma Dynavax Technologies Corporation partners with AstraZeneca to advance AZD 1419 … |
View full post on asthma – Google News